BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35858516)

  • 1. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
    Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
    Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.
    Meng ZW; Zhang L; Cai XR; Wang X; She FF; Chen YL
    Sci Rep; 2023 Oct; 13(1):18711. PubMed ID: 37907543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
    Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a.
    Zhu X; Bao W; Xie X; Chen B; Li R; Zhao J; Wu L; Yu Z; Li S; Zhu Q; Chen G; Li J
    Mol Carcinog; 2024 Apr; 63(4):772-784. PubMed ID: 38289159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma.
    Lang Q; Xiao P; Zhao M; Liang D; Meng Q; Pei T
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1247-1256. PubMed ID: 33166992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.
    Wang T; Chen Z; Chen H; Yu X; Wang L; Liu X
    J Ethnopharmacol; 2022 Apr; 288():115020. PubMed ID: 35066068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway.
    Li L; Wang C; Qiu Z; Deng D; Chen X; Wang Q; Meng Y; Zhang B; Zheng G; Hu J
    Phytomedicine; 2023 Jan; 109():154575. PubMed ID: 36610163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
    Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
    Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
    J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells.
    Deng G; Hu C; Zhu L; Huang F; Huang W; Xu H; Nie W
    Int J Mol Med; 2014 Sep; 34(3):661-8. PubMed ID: 24968753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
    Deng S; Zhang L; Li J; Jin Y; Wang J
    Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
    Acharya B; Chaijaroenkul W; Na-Bangchang K
    J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
    Acharya B; Chajaroenkul W; Na-Bangchang K
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.